Truist Securities maintains Edwards Lifesciences at Buy, raises price target to $118 from $113
Meno di 1 minuto di lettura
Truist Securities maintained Edwards Lifesciences at Buy and raised its price target to $118 from $113, a 4.4% increase.
The price target implies an upside of 18.7% from the Nov 4 close of $99.37.
Recent analyst actions on Edwards Lifesciences
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Wells Fargo | Maintains | Overweight | $113 |
| Nov 5 | Evercore ISI Group | Maintains | Outperform | $112 |
| Nov 5 | BTIG | Maintains | Buy | $115 |
| Nov 4 | Truist Securities | Upgrades | Buy | $113 |
| Oct 7 | Barclays | Initiates Coverage On | Overweight | $110 |
Across the five most recent analyst notes published on Edwards Lifesciences over the past 30 days, price targets range from $110 to $115.
Explore more price target data and ratings for Edwards Lifesciences on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
Leggi l'articolo completo
Ottieni accesso illimitato agli aggiornamenti degli analisti e a tutti gli altri articoli su TradingView.